Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)
-
Published:2024-07
Issue:
Volume:193
Page:107843
-
ISSN:0169-5002
-
Container-title:Lung Cancer
-
language:en
-
Short-container-title:Lung Cancer
Author:
Amari Lyria, Tomasini Pascale, Dantony EmmanuelleORCID, Rousseau-Bussac Gaelle, Ricordel Charles, Bigay-Game Laurence, Arpin Dominique, Morel Hugues, Veillon Remi, Justeau Grégoire, Huchot Eric, Fournel PierreORCID, Vergnenegre Alain, Bizeux AcyaORCID, Subtil FabienORCID, Clarisse Bénédicte, Decroisette Chantal, Chouaid ChristosORCID, Greillier LaurentORCID, Bylicki Olivier
Reference34 articles.
1. AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M–Positive Lung Cancer;Mok;N Engl J Med.,2017 2. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China;Cheng;A Randomized Study. Targ Oncol.,2021 3. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):339-357. doi: 10.1016/j.annonc.2022.12.009. 4. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management;Cooper;Nat Rev Clin Oncol.,2022 5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016
|
|